WO2011112875A3 - Foamable formulation - Google Patents

Foamable formulation Download PDF

Info

Publication number
WO2011112875A3
WO2011112875A3 PCT/US2011/028004 US2011028004W WO2011112875A3 WO 2011112875 A3 WO2011112875 A3 WO 2011112875A3 US 2011028004 W US2011028004 W US 2011028004W WO 2011112875 A3 WO2011112875 A3 WO 2011112875A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
formulation
dmso
active agent
methods
Prior art date
Application number
PCT/US2011/028004
Other languages
French (fr)
Other versions
WO2011112875A2 (en
Inventor
Servet Buyuktimkin
Nadir Buyuktimkin
Edward T. Kisak
Jagat Singh
John M. Newsam
Dominic King-Smith
Bradley S. Galer
Original Assignee
Nuvo Research Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvo Research Inc. filed Critical Nuvo Research Inc.
Priority to EP11713105.2A priority Critical patent/EP2544662B1/en
Priority to CA2828086A priority patent/CA2828086C/en
Publication of WO2011112875A2 publication Critical patent/WO2011112875A2/en
Publication of WO2011112875A3 publication Critical patent/WO2011112875A3/en
Priority to US13/605,734 priority patent/US9107823B2/en
Priority to US14/791,210 priority patent/US9861579B2/en
Priority to US15/827,495 priority patent/US10646441B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Abstract

The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen.
PCT/US2011/028004 2010-03-10 2011-03-10 Foamable formulation WO2011112875A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP11713105.2A EP2544662B1 (en) 2010-03-10 2011-03-10 Foamable formulation
CA2828086A CA2828086C (en) 2010-03-10 2011-03-10 Foamable formulation
US13/605,734 US9107823B2 (en) 2010-03-10 2012-09-06 Foamable formulation
US14/791,210 US9861579B2 (en) 2010-03-10 2015-07-02 Foamable formulation
US15/827,495 US10646441B2 (en) 2010-03-10 2017-11-30 Foamable formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31262910P 2010-03-10 2010-03-10
US61/312,629 2010-03-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/605,734 Continuation US9107823B2 (en) 2010-03-10 2012-09-06 Foamable formulation

Publications (2)

Publication Number Publication Date
WO2011112875A2 WO2011112875A2 (en) 2011-09-15
WO2011112875A3 true WO2011112875A3 (en) 2012-05-10

Family

ID=44069551

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/028004 WO2011112875A2 (en) 2010-03-10 2011-03-10 Foamable formulation

Country Status (4)

Country Link
US (3) US9107823B2 (en)
EP (1) EP2544662B1 (en)
CA (1) CA2828086C (en)
WO (1) WO2011112875A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112875A2 (en) 2010-03-10 2011-09-15 Nuvo Research Inc. Foamable formulation
AU2012250664B2 (en) 2011-05-03 2017-04-20 Aponia Laboratories, Inc. Transdermal compositions of ibuprofen and methods of use thereof
ITMI20121205A1 (en) 2012-07-11 2014-01-12 Glycores 2000 Srl COMPOSITION WITH ANTI-INFLAMMATORY AND ANALGESIC ACTIVITY TO BE GIVEN FOR EXTERNAL USE BY VAPORIZATION
US20140113970A1 (en) * 2012-10-22 2014-04-24 Mallinckrodt LLC Covidien Dispensing system
AU2013361106B2 (en) 2012-12-21 2017-06-01 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
KR101586791B1 (en) 2012-12-28 2016-01-19 주식회사 종근당 Sustained-release lipid pre-concentrate of GnRH analogues and pharmaceutical composition comprising the same
KR101586789B1 (en) * 2012-12-28 2016-01-19 주식회사 종근당 Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same
EP3010487A4 (en) * 2013-06-17 2016-12-07 Contract Pharmaceuticals Ltd Non-aerosol foams for topical administration
US9855234B2 (en) * 2014-07-08 2018-01-02 Insys Development Company, Inc. Diclofenac sublingual spray
US10912811B1 (en) * 2014-10-28 2021-02-09 Felician Stancioiu Composition for improving peripheral circulation and healing of hematomas
JP6703987B2 (en) * 2014-11-10 2020-06-03 アケリオス セラピューティクス，インコーポレーテッド Sprayable analgesic composition
WO2021061913A1 (en) * 2019-09-27 2021-04-01 Encube Ethicals, Pvt. Ltd. Diclofenac sodium topical solution
WO2023180792A1 (en) 2022-03-25 2023-09-28 Glycores 2000 Srl Topical pharmaceutical composition with anti-inflammatory and analgesic activity and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032227A2 (en) * 2006-09-11 2008-03-20 Biomas, Ltd. Topical formulations of tellurium-containing compounds
WO2008038147A2 (en) * 2006-07-05 2008-04-03 Foamix Ltd. Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
WO2008038140A2 (en) * 2006-06-07 2008-04-03 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
WO2010125470A2 (en) * 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS1740B (en) 1982-02-05 1999-12-31 Albright & Wilson Uk Limited Composition of cleaning liquid
US4478853A (en) 1982-05-17 1984-10-23 S. C. Johnson & Son, Inc. Skin conditioning composition
CA1236029A (en) 1984-05-14 1988-05-03 Edmund Sandborn Pharmaceutical solutions comprising dimethyl sulfoxide
DE3632359A1 (en) * 1986-09-24 1988-04-07 Troponwerke Gmbh & Co Kg PREPARATIONS FOR MEDICINAL PRODUCTS
US5322683A (en) 1989-05-01 1994-06-21 Leonard Mackles Anhydrous aerosol foam
GB9114255D0 (en) 1991-07-02 1991-08-21 Unilever Plc Cosmetic composition
GB2260079B (en) 1991-10-01 1995-08-09 American Cyanamid Co Pharmaceutical composition containing felbinac
US5443369A (en) 1993-06-09 1995-08-22 Ingersoll-Rand Company Self-contained instrument and seal air system for a centrifugal compressor
US5540853A (en) * 1994-10-20 1996-07-30 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
NL1001366C2 (en) 1995-10-06 1997-04-08 Airspray Int Bv Device for dispensing an air-liquid mixture, in particular foam and operating unit intended for this purpose.
CN1105605C (en) 1998-04-17 2003-04-16 克尔图布公司 Foam spraying device
JP2001329190A (en) * 2000-05-24 2001-11-27 Masao Umemoto Coating-peeling agent and peeling device
US6818204B2 (en) 2000-06-23 2004-11-16 Combe Incorporated Stable foam for use in disposable wipe
NL1016694C2 (en) 2000-11-23 2002-05-24 Keltub B V Foam forming unit.
CA2446060A1 (en) 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
US20050239675A1 (en) * 2002-04-01 2005-10-27 Munzer Makansi Carrier foam to enhance liquid functional performance
MXPA05004278A (en) * 2002-10-25 2005-10-05 Foamix Ltd Cosmetic and pharmaceutical foam.
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20070292359A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
NL1022633C2 (en) 2003-02-10 2004-08-12 Keltub B V Improved foaming unit.
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
NL1024350C2 (en) 2003-09-23 2005-03-24 R & D Injector Ag Delivery unit for concentrated injection.
KR100866653B1 (en) 2004-06-29 2008-11-04 아사히 가세이 케미칼즈 가부시키가이샤 Flame-retardant epoxy resin composition
JP4776193B2 (en) 2004-09-07 2011-09-21 Ｎｔｎ株式会社 Grease composition for automobile wheel bearing
US20060078599A1 (en) * 2004-10-12 2006-04-13 Mathew Ebmeier Pharmaceutical composition applicable to body tissue
NL1028827C2 (en) 2005-04-20 2006-10-23 Keltec B V Delivery unit.
NL1030030C2 (en) 2005-04-20 2006-10-23 Keltec B V Dispensing unit with improved supply shut-off means.
NL1028921C2 (en) 2005-04-29 2006-11-01 Airspray Nv Dispensing device.
US7651990B2 (en) 2005-06-13 2010-01-26 3M Innovative Properties Company Foamable alcohol compositions comprising alcohol and a silicone surfactant, systems and methods of use
US20080152596A1 (en) * 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
WO2007070983A1 (en) 2005-12-22 2007-06-28 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
NL1030992C2 (en) 2006-01-24 2007-07-26 Airspray Nv Squeeze foamer.
WO2008007943A1 (en) 2006-07-11 2008-01-17 Rexam Airspray N.V. Foam dispenser
US7735692B2 (en) 2006-10-10 2010-06-15 Meadwestvaco Calmar, Inc. Rotating dispenser head with locking and venting closure connector for an air foaming pump dispenser
RU2463038C2 (en) 2006-10-17 2012-10-10 Нуво Рисерч Инк. Diclofenac gel
EP2073794A2 (en) * 2006-11-14 2009-07-01 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
PE20081406A1 (en) * 2006-12-20 2008-10-17 Schering Plough Ltd PHARMACEUTICAL COMPOSITIONS OF FLUNIXIN
US20080292560A1 (en) 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
US8356732B2 (en) 2007-04-26 2013-01-22 Rexam Airspray N.V. Dispensing device
WO2009038452A1 (en) 2007-09-17 2009-03-26 Rexam Airspray N.V. Foam dispensing assembly
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
WO2009136781A1 (en) 2008-05-06 2009-11-12 Rexam Airspray N.V. Squeeze foamer
CN101797239B (en) 2009-02-05 2012-09-05 北京因科瑞斯医药科技有限公司 Strychnos alkaloid vesicle and preparation method thereof
BR112012012789A2 (en) * 2009-11-27 2016-08-16 Nuvo Res Inc topical ibuprofen formulations
WO2011112875A2 (en) 2010-03-10 2011-09-15 Nuvo Research Inc. Foamable formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008038140A2 (en) * 2006-06-07 2008-04-03 Foamix Ltd. Foamable vehicle comprising polypropylene glycol alkyl ether and pharmaceutical compositions thereof
WO2008038147A2 (en) * 2006-07-05 2008-04-03 Foamix Ltd. Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
WO2008032227A2 (en) * 2006-09-11 2008-03-20 Biomas, Ltd. Topical formulations of tellurium-containing compounds
WO2010125470A2 (en) * 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof

Also Published As

Publication number Publication date
US20130243701A1 (en) 2013-09-19
EP2544662A2 (en) 2013-01-16
US10646441B2 (en) 2020-05-12
US9861579B2 (en) 2018-01-09
WO2011112875A2 (en) 2011-09-15
US20150297518A1 (en) 2015-10-22
EP2544662B1 (en) 2020-05-20
CA2828086C (en) 2018-07-31
US20180147144A1 (en) 2018-05-31
CA2828086A1 (en) 2011-09-15
US9107823B2 (en) 2015-08-18

Similar Documents

Publication Publication Date Title
WO2011112875A3 (en) Foamable formulation
AR124134A2 (en) TOPICAL USE FORMULATION FOR A JAK INHIBITOR
BR112012015755A8 (en) lipids, lipid compositions, and methods of use thereof
WO2015184127A3 (en) Stable cannabinoid formulations
UY33440A (en) ? PYRIMIDINYL COMPOUNDS FOR USE AS ATR INHIBITORS ?.
ECSP109917A (en) NEW DERIVATIVES OF AZABIFENILAMINOBENZOIC ACID
CL2011002053A1 (en) Pharmaceutical foam composition in oil-in-water emulsion spray comprising a pharmaceutically active agent, water, oil, organic solvent, surfactant component, and propellant; preparation procedure; Use to treat diseases, or skin conditions.
EP2223703A4 (en) External preparation composition comprising fatty acid-based ionic liquid as active ingredient
GT201300137A (en) IMIDAZO DERIVATIVES [1,2-B] PIRIDAZINE AND IMIDAZO [4,5-B] PIRIDINA AS JAK INHIBITORS
CL2013001459A1 (en) Compounds derived from quinazolincarboxamide azetidine; process to prepare them; pharmaceutical composition that includes them; set (kit); and its use for the treatment of hyperproliferative diseases such as cancer, inflammation, pancreatitis or kidney disease, pain, benign skin hyperplasia among others.
WO2009053741A3 (en) Novel formulation
CL2012003039A1 (en) Polyethylene glycol conjugated to factor viii through a linker group; pharmaceutical composition comprising said conjugated polyethylene glycol; use of said composition for treatment of a disease or trauma of blood clotting.
EP2152279A4 (en) Use of biological surfactant as anti -inflammatory agent and tissue preservative solution.
MX2018001584A (en) SOLID SOLUTION COMPOSITIONS FOR NSAIDs.
CL2013000866A1 (en) Oxalolate and phosphate crystalline salts of the naloxolpolyethylene glycol conjugate; Preparation method; pharmaceutical composition that includes it; and its use for the treatment of pain.
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
WO2012147101A3 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
JP2015511618A5 (en)
BRPI0908518A2 (en) stable fixed dose topical formulation and use of stable fixed dose topical formulation
PL2590620T3 (en) Stable aqueous formulations comprising poorly water soluble active ingredients
MX2012010935A (en) Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlo robenzyl sulfone.
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
WO2011041609A3 (en) Topical formulations
BR112012016736A2 (en) composition, pharmaceutical formulation and use of composition "
WO2015087267A3 (en) Stable bromfenac ophthalmic solution

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11713105

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011713105

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2828086

Country of ref document: CA